

Fig. 2 In situ hybridization for ADA mRNA. Small intestines were harvested 24 h after the second injection of IND





Fig. 3 OGT reduced ADA mRNA expression in the small intestines of both IND-treated and untreated mice. Small intestines were harvested at 24 h after the second injection of IND. * $P < 0.05$, t test with Bonferroni correction. Data represent the means \pm SEM ($n = 3-5$ per group)




Fig. 4 Adenosine A2a receptor antagonist abrogates the effect of OGT. Adenosine A2a receptor antagonist (CSC; 10 mg/kg i.p.) was injected for 5 consecutive days prior to the first injection of IND. Survival curves were drawn using the Kaplan–Meier method and statistical analysis was done by the logrank test. * $P < 0.02$ versus IND + OGT ($n = 15$ per group)





Fig. 5 a Effect of OGT fractions on IND-induced lethality. Diets containing each fraction at the concentration relevant to that in 2%OGT were administered from the first injection of IND until the end of the experiments. HMW: high molecular weight fraction. The alkaloid fraction had the strongest protective effect. Survival curves were drawn using the Kaplan–Meier method ($n = 10$ per group). **b** Berberine suppressed IND-induced lethality in a dose-dependent manner. Diets containing berberine at 1 \times [Ber(1)], 2 \times [Ber(2)] or 3 \times [Ber(3)] concentration corresponding to that in 2% OGT were administered from the first IND injection until the end of the experiment. Survival curves were drawn using the Kaplan–Meier method ($n = 10$ per group)

inflammatory state, large amounts of extracellular adenosine are produced from ATP via the successive conversion by CD73/ectonucleotidase (Nt5e) and CD39 (Entpd2) and degraded by ectopically expressed ADA. Extracellular

adenosine binds to adenosine receptors (A2a, A2b) and transduces signals to MAPK1 and 3 through relevant G proteins (Gna11, Gnai2, Gnai3, Gnao1 and Gnas3). HIF1A is a master transcription factor which regulates the large portion of genes involved in the adenosine system. The expression of other relevant genes such as endonucleotidase (Nt5c2), nucleotide transporters (Slc28 family and Slc29 family), adenosine A1 and A3 receptors (Adora1, Adora3) were not detected nor assessed in the present study. The fold change and *P*-value for each gene provided by GeneChip analysis are represented as the size of icon and the line thickness of the wraparound frame, respectively. The figure clearly shows IND predominantly




Fig. 6 Berberine reduced ADA mRNA expression in the small intestine. Small intestines were harvested at 24 h after the second injection of IND. Diet containing berberine at twice the concentration corresponding to that in 2% OGT was administered from the first IND injection until the end of experiment. **P* < 0.05, *t* test with Bonferroni correction. Data represent the means ± SEM (*n* = 5 per group)


activates gene expression involved in extracellular adenosine metabolism. This suggests that in IND-treated small intestines a large amount of adenosine is synthesized and then degraded resulting in activation of the adenosine signal transduction pathway. OGT normalizes the changes induced by IND treatment.

Discussion

Several pathogenic factors of IND-induced enteropathy have been suggested [13, 14], which were PGs depletion after COX inhibition [15], increase of intestinal permeability after mitochondrial damage [16], exposure of luminal bacteria to mucosa [9], oxidative stress [17], nitric oxide [10], TNF- α [18], neutrophil infiltration [19] and microcirculatory changes [20–22].

In the present study, we demonstrated that the adenosine system, including ADA, plays an important role in IND-induced enteropathy and its amelioration by OGT, which indicates that the adenosine system is another option of the mechanism and therapeutic target of IND-induced enteropathy. Adenosine is a ubiquitous endogenous purine nucleoside, which exerts its various biological actions in many organs via cell surface adenosine receptors (A1, A2a, A2b, A3) [23]. Normally the extracellular adenosine concentration is strictly controlled by a set of synthetic, transport and metabolic molecules. However, in response to cellular damage (e.g. inflammation or ischemia), adenosine concentration is quickly elevated, which plays a prominent role in modulating inflammation and helps to maintain tissue integrity [24]. The cytoprotective functions

Fig. 7 Schematic representation of changes in gene expression of the adenosine system using Cell Illustrator Online (CIO). *NT5E* CD73/ectonucleotidase, *ADA* adenosine deaminase, *ADORA* adenosine receptor, *HIF1A* hypoxia inducible factor 1A, *GNA* G protein, *ADK* adenosine kinase



of adenosine have been suggested in several experimental colitis models by modulation of adenosine signaling. Indeed, adenosine has been proposed to form the basis of a novel therapeutic option for inflammatory bowel diseases (IBDs) [25, 26]. Furthermore, the prominent role of A2a receptors suggested by the present results is in good accordance with previous reports on both acute and chronic colitis models [27, 28].

Here, we showed that OGT decreased ADA mRNA expression which was increased by injection of IND. ADA is an enzyme that is largely responsible for the degradation of adenosine. The cellular concentration of adenosine is determined by the net balance of adenosine synthesis, transport and catabolism. Therefore, it is possible that OGT may increase the adenosine concentration by decreasing the amount of ADA. Inhibition of ADA as a possible therapeutic option for enteropathy was also suggested in a report by Antonioli et al. [29] where it was shown that an ADA inhibitor attenuates DNBS colitis. Survey and analysis of the results of microarray data (Fig. 7; Table 3) suggested that the genes involved in extracellular adenosine metabolism are most profoundly affected, which support the hypothesis that the effect of IND/OGT is closely related to the extracellular concentration of adenosine. Furthermore, because OGT decreased ADA mRNA in normal mice, the decrease of ADA may not be the result of a reduction in inflammation but an independent action executed by OGT.

Pouliot et al. [30] showed that adenosine upregulated COX-2 enzyme in human granulocytes, and suggested that adenosine might promote a self-limiting regulatory process through the increase of PGE2 generation. In our previous study, we showed that OGT elicited an increase in the number of COX-2 expressing cells in the lamina propria and in the production of mucosal PGE2. These observations could be explained in terms of an increase in the concentration of adenosine due to inhibition of ADA activity. However, because we did not determine the adenosine concentration, further extensive studies are necessary to clarify this point.

Investigation of active components using major isoquinoline alkaloids of OGT has revealed that two berberine-like alkaloids, berberine and coptisine, display preventive activity on IND-induced death. We focused the attention of the effects of berberine, because the alkaloid is readily available and ethically used in Japan. Berberine reduced the lethality by IND and decreased ADA mRNA expression in the small intestine (Figs. 5b, 6). However, treatment with berberine alone did not have sufficient efficacy on the lethality even if the dose was increased (Fig. 5b). Thus, we believe that additional ingredients may be responsible for the potent preventive effect of OGT against enteropathy.

In conclusion, guided by a transcriptome approach using MGP analysis, we have demonstrated the importance of the adenosine system in IND-induced enteropathy and its amelioration by OGT/berberine. This study addresses the possible efficacy of OGT as a treatment option for the adverse effect of NSAIDs on the small intestine. We believe that modulation of the adenosine system may provide an effective therapeutic strategy for NSAID-induced enteropathy.

References

- Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. *Clin Gastroenterol Hepatol.* 2005;3:133–41.
- Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. *Gastroenterology.* 2005;128:1172–8.
- Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. *Clin Gastroenterol Hepatol.* 2005;3:55–9.
- Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. *Gastroenterology.* 1993;104:1832–47.
- Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. *Dig Dis Sci.* 1989;34:407–11.
- Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. *J Gastroenterol.* 2008;43:270–6.
- Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. *Clin Gastroenterol Hepatol.* 2007;5:1040–5.
- Miura N, Fukutake M, Yamamoto M, Ohtake N, Iizuka S, Imamura S, et al. An herbal medicine orengedokuto prevents indomethacin-induced enteropathy. *Biol Pharm Bull.* 2007;30:495–501.
- Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. *Prostaglandins.* 1977;14:333–41.
- Whittle BJ, Laszlo F, Evans SM, Moncada S. Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. *Br J Pharmacol.* 1995;116:2286–90.
- Yamaguchi R, Yamamoto M, Imoto S, Nagasaki M, Yoshida R, Tsuji K, et al. Identification of activated transcription factors from microarray gene expression data of Kampo medicine-treated mice. *Genome Inform.* 2007;18:119–29.
- Nagasaki M, Doi A, Matsuno H, Miyano S. Genomic Object Net: I. A platform for modelling and simulating biopathways. *Appl Bioinformatics.* 2003;2:181–4.
- Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. *J Gastroenterol.* 1997;32:127–33.
- Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. *Pharmacol Res.* 1999;40:517–24.

15. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol.* 1971;231:232–5.
16. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. *Gut.* 1997;41:344–53.
17. Basivireddy J, Vasudevan A, Jacob M, Balasubramanian KA. Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes. *Biochem Pharmacol.* 2002;64:339–49.
18. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, et al. Increase in tumor necrosis factor- α production linked to the toxicity of indomethacin for the rat small intestine. *Br J Pharmacol.* 1998;124:1385–94.
19. Antoon JS, Perry MA. Role of neutrophils and mast cells in acute indomethacin-induced small bowel injury in the rat. *J Gastroenterol.* 1997;32:747–57.
20. Miura S, Suematsu M, Tanaka S, Nagata H, Houzawa S, Suzuki M, et al. Microcirculatory disturbance in indomethacin-induced intestinal ulcer. *Am J Physiol.* 1991;261:G213–9.
21. Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T. Reduced conscious blood flow in the stomach during non-steroidal anti-inflammatory drugs administration assessed by flash echo imaging. *Scand J Gastroenterol.* 2007;42:1040–4.
22. Nishizawa T, Suzuki H, Masaoka T, Hibi T. Education and imaging. Gastrointestinal: enhanced gastric mucosal blood flow in aspirin intoxication. *J Gastroenterol Hepatol.* 2007;22:2037.
23. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev.* 2001;53:527–52.
24. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. *Trends Immunol.* 2004;25:33–9.
25. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, et al. Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. *Inflamm Bowel Dis.* 2008;14:566–74.
26. Kolachala VL, Bajaj R, Chalasani M, Sitaraman SV. Purinergic receptors in gastrointestinal inflammation. *Am J Physiol Gastrointest Liver Physiol.* 2008;294:G401–10.
27. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. *Gastroenterology.* 2005;129:26–33.
28. Cavalcante IC, Castro MV, Barreto AR, Sullivan GW, Vale M, Almeida PR, et al. Effect of novel A2A adenosine receptor agonist ATL 313 on *Clostridium difficile* toxin A-induced murine ileal enteritis. *Infect Immun.* 2006;74:2606–12.
29. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G, et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. *J Pharmacol Exp Ther.* 2007;322:435–42.
30. Pouliot M, Fiset ME, Masse M, Naccache PH, Borgeat P. Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. *J Immunol.* 2002;169:5279–86.

Tumor necrosis factor- α mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia*

Satoshi Yajima, MD; Hiroshi Morisaki, MD; Ryohei Serita, MD; Takeshi Suzuki, MD; Nobuyuki Katori, MD; Takashi Asahara, PhD; Koji Nomoto, PhD; Fujio Kobayashi, BA; Akitoshi Ishizaka, MD; Junzo Takeda, MD

Objective: To examine whether hyperglycemia would augment gut barrier dysfunction and inflammatory responses in endotoxemic rats, and simultaneously to clarify the roles of tumor necrosis factor (TNF)- α in alterations of gut mucosal permeability associated with hyperglycemia.

Design: Prospective randomized animal study.

Setting: University research laboratory.

Subjects: Male Wistar rats treated with lipopolysaccharide (LPS) injection.

Interventions: After LPS injection (4 mg/kg), rats were randomly allocated into group S (n = 6), group G (n = 7), or group GI (n = 8) with continuous infusion of different fluid solutions: normal saline, 40% glucose or 10% glucose mixed with insulin, respectively. Blood glucose, insulin, and proinflammatory cytokines, accompanied by gut mucosal permeability using an *in situ* loop preparation of gut with fluorescence isothiocyanate-conjugated dextran, were measured. Bacterial growth or alterations in mesenteric lymph nodes and cecal contents were also assessed. We further determined the roles of TNF- α using an inhibitor of TNF- α converting enzyme in gut barrier dysfunction under the same experimental settings.

Measurements and Main Results: Hyperglycemia over 400 mg/dL was achieved and kept in group G during the study period whereas normoglycemia was preserved in group S and GI, the latter of which showed the similar extent of hyperinsulinemia to group G. Plasma concentrations of fluorescence-labeled dextran and TNF- α in group G were significantly higher vs. group S and GI, and the number of bacteria found in mesenteric lymph nodes in group G was greater compared with group S. Intestinal environments including microflora and organic acids were not altered by blood glucose or insulin level. Inhibiting conversion of membrane-bound to soluble type of TNF- α restored gut mucosal permeability augmented by hyperglycemia.

Conclusions: These findings indicate that hyperglycemia deteriorates LPS-elicited gut barrier dysfunction and bacterial translocation independently of plasma insulin level, and that TNF- α mediates such mucosal dysfunction of gut in endotoxemia. (Crit Care Med 2009; 37:1024-1030)

KEY WORDS: hyperglycemia; insulin; endotoxin; TNF- α converting enzyme; gut mucosal permeability

Hyperglycemia has been recognized as a consequential risk factor to increase the mortality and morbidity in critically ill even without diabetes mellitus (1, 2). Clinical trials demonstrated that intensive insulin therapy to regulate blood glucose level <110 mg/dL improved the outcome of both medical and surgical patients who were admitted in intensive care units (3, 4), whereas the most recent study

alarmed that such tight control of blood glucose increased a potential threat for serious adverse events associated with hypoglycemia (5). Previous reports showed that acute hyperglycemia enhanced systemic inflammatory responses including oxidative stress and cytokine production (6), which were lessened by hyperinsulinemic euglycemia in animal models of endotoxemia (7). Although a multivariate analysis of the clinical data suggests that normoglycemia is the key factor rather than insulin infusion to improve the outcome (8), insulin by itself attenuated endotoxin-induced increases of nitric oxide (NO) and superoxide production, and subsequently slowed the progression of lung injury (9). Nevertheless, it still remains unclear which factor, keeping normoglycemia or plasma insulin level, is the determinant to improve the outcome in critically ill.

Despite being long considered as a non-vital organ, gut has now become one of therapeutic targets in critically ill (10). A loss of barrier function, regulated by several factors such as NO and tumor necrosis fac-

tor (TNF)- α (11, 12), permits an invasion of intraluminal bacteria and/or toxins into systemic bloodstream and lymph nodes, subsequently augments systemic inflammatory responses and the development of multiple organ failure (10). Because hyperglycemia modulates inflammatory responses involving both NO and TNF- α (13), we hypothesized that hyperglycemia damaged gut mucosa and evoked bacterial translocation, resulting in the increase of modality-like positive blood culture as shown in clinical trials (3, 4). In addition, excessive abnormality of bacterial flora in gut is another element to induce bacterial translocation and to determine the outcome in critically ill (14). In an endotoxemic rat model, we, therefore, evaluated the effects of hyperglycemia and plasma insulin level on gut barrier function, intestinal flora, and production of proinflammatory cytokines. As a second aim of this study, we further examined the roles of TNF- α in the relationship between hyperglycemia and gut barrier dysfunction in endotoxemia.

*See also p. 1160.

From the Departments of Anesthesiology (SY, RS, TS, NK, HM, JT), and Medicine (AI), Keio University School of Medicine, Tokyo, Japan; Yakult Central Institute for Microbiological Research (TA, KN), Tokyo, Japan; Research & Development Division (FK), Tanabe-Mitsubishi Pharma Corporation, Yokohama, Japan.

Supported by funds from Keio Medical Research Funds and Yakult Bioscience Foundation.

The authors have not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: morisaki@z8.keio.jp

Copyright © 2009 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/CCM.0b013e31819b53b6

METHODS

This study protocol was approved by the animal care and use committee of Keio University School of Medicine in accordance with the National Institute of Health.

Animal Model. Male Wistar rats, weighing 220–250 g, were studied after a 3–7 days period of acclimatization in our laboratory. With isoflurane anesthesia in oxygen, the jugular vein and carotid artery were cannulated with a catheter (PE50; Intermedic, Sparks, MD) under sterile condition. After this preparation, the animals were placed in a metabolic cage that allowed time for awakening and stabilization for 1 hour. Arterial catheter was connected to a pressure transducer (Nihon Kohden, Tokyo, Japan) to record the mean arterial pressure and heart rate on a polygraph recorder (Power lab, AD Instruments, Mountain View, CA). Then, all animals received intravenous injection of 4 mg/kg lipopolysaccharide (LPS) (*Escherichia coli*, Sigma Chemicals, St. Louis, MO) and fluid therapy for the next 3 hours.

Study Protocol 1. After the preparatory surgery described above, 21 animals were randomized into three groups using a computer-generated random number: group S (n = 6) received intravenous infusion of normal saline, group G (n = 7) received 40% glucose solution (Ohtsuka Pharma, Tokushima, Japan), and group GI (n = 8) received 10% glucose solution (Ohtsuka Pharma) mixed with insulin (8 mU·kg⁻¹·min⁻¹) (Insulin Human, Novolin-R injection, Novo-Nordisk, Copenhagen, Denmark). All solutions were infused at the rate of 10 mL·kg⁻¹·hr⁻¹. The target glucose level in group G was 300–350 mg/dL commonly applied in previous experimental studies (15, 16) whereas those in group S and GI were ranged at 80–110 mg/dL as described by van den Berghe et al (3, 4). Our pilot study showed a continuous infusion of glucose and insulin mixture reached approximately within each blood glucose range, accompanied by hyperinsulinemia in rats. Arterial blood was sampled for measuring blood glucose levels (ACCU-check; Roche Diagnostics, Basel, Switzerland) at baseline, 1, 2, and 3 hour after the randomization. Simultaneously, at 3-hour study period, plasma concentration of insulin, cytokines, and nitric oxide metabolites (NOx) were measured. Thereafter, laparotomy was performed under isoflurane anesthesia and sterile condition for the examination of gut mucosal permeability. In a separate series of experiments, sampling of mesenteric lymph nodes (MLNs) and cecal contents for the assessment of intestinal flora from 21 animals (group S: n = 6, group G: n = 7, and group GI: n = 8) was performed as described below. To evaluate intestinal microbes and plasma insulin level in normal rats, we analyzed the samples obtained from four sham rats which received the same catheterization and fluid therapy with saline without LPS injection.

Study Protocol 2. Following the catheterization, another 32 rats which received the same amount of LPS were randomized into

four groups: group S (n = 8) received normal saline, group ST (n = 9) received normal saline containing 0.3 mg/mL of tumor necrosis factor converting enzyme (TACE) inhibitor (Y-41654; Tanabe-Mitsubishi Pharma, Osaka, Japan), group G (n = 8) received 40% glucose solution, and group GT (n = 7) received 40% glucose solution containing 0.3 mg/mL of Y-41654. All solutions were infused at the rate of 10 mL·kg⁻¹·hr⁻¹. At the 3-hour study period, arterial blood was obtained for measurements of several markers described in Study Protocol 1 section, and thereafter laparotomy was performed for examination of gut mucosal permeability as described below. Y-41654, a water-soluble compound with a molecular weight of approximately 700 and a half-life of 30 minutes in rat blood, has a peptide-mimicking hydroxamate structure which facilitates chelation of the zinc ion in the active site of the TACE. This compound was found to show high potency against TACE in substrate assays (data not shown), suggesting that it behaves as a competitive inhibitor.

Measurements of Gut Mucosal Permeability. We determined gut mucosal permeability by using fluorescein isothiocyanate-conjugated dextran (FD4) with a molecular weight of 4000 Da, as described previously (17). Briefly, the abdomen was opened for preparation of an *in situ* loop of gut. After removal of undigested food in observed segment of ileum with phosphate-buffered saline (pH 7.4), double ligatures at both ends were made on the 10-cm length of terminal ileum. Through a cannula placed into this segment of terminal ileum, FD4 (10 mg in 1 mL of phosphate-buffered saline, Sigma, St. Louis, MO) was injected, which resulted in a slight distension of intestinal loop. After 30 minutes, blood samples from both portal vein and artery were obtained and centrifuged, and plasma FD4 concentrations were measured at an excitation wavelength of 480 nm and an emission wavelength of 520 nm using fluorescence spectrometry (Spectrofluorophotometer: RF-1500, Shimadzu, Kyoto, Japan). Results were corrected for plasma protein contents measured by Lowry method.

Sampling of MLNs and Cecal Contents. To perform the sampling of MLNs and cecal contents under sterile condition, another 21 rats, which were randomized and treated with fluid therapy for 3 hours according to Study Protocol 1, were examined. After laparotomy, cecum and distal ileum were externalized, and three MLNs in each rat were randomly sampled and homogenized in 0.5 mL sterilized phosphate buffer solution. The MLNs in phosphate buffer solution were submerged in RNAlater (Ambion, Austin, TX), followed by being stored under conditions where RNA degradation would normally take place rapidly. Blood (1 mL) obtained from portal vein was mixed with sodium citrate (0.38%, wt/vol) and RNAlater (Qiagen, Hilden, Germany). Thereafter, a 10-cm segment of distal ileum was dissected and its contents were collected into the tube including 2 mL RNAlater and mixed vigorously for the examination of gut flora in MLNs as described below. The contents

of cecum were collected for examination of organic acid concentrations and pH as described below. All samples were weighed and stored at –20°C until further examinations.

Determination of RNA, Bacteria, and Organic Acid Concentrations in Gut or MLNs. After serial 1/10 dilutions of all samples were made in RNAlater, they were added to two volumes of RNAlater™ bacterial reagent, and then the preparations were incubated for 5 minutes at room temperature. After centrifugation of each mixture at 5000 g for 10 minutes, the supernatant was discarded and the pellet was stored at –80°C until it was used for extraction of RNA. RNA was isolated using the method described elsewhere (18). Finally, the nucleic acid fraction was suspended in 50 µL-nuclease-free water. A standard curve was generated with reverse transcription-quantitative polymerase chain reaction data (using the threshold cycle [C_T] value, the cycle number when the threshold fluorescence was reached) and the corresponding cell count, which was determined microscopically with 4,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) staining (19) for dilution series of the standard strains described elsewhere (20). For determination of the bacteria presented in samples, three serial dilutions of an extracted RNA sample were used for reverse transcription-quantitative polymerase chain reaction, and the C_T values in the linear range of the assay were applied to the standard curve generated in the same experiment to obtain the corresponding bacterial cell count in each nucleic acid sample and then converted to the number of bacterial per sample. The specificity of the reverse transcription-quantitative polymerase chain reaction assay using the group- or species-specific primers was determined as described previously (20).

The contents of cecum were homogenized in 1 mL distilled water, and centrifuged at 10,000 rpm at 4°C for 10 minutes. A mixture of 0.9 mL of the resulting supernatant and 0.1 mL of 1.5 mol/L perchloric acid was mixed in a glass tube, and allowed to stand at 4°C for 12 hours. The suspension was then passed through a filter with a pore size of 0.45 µm (Millipore Japan, Tokyo). The sample was analyzed for organic acids by high-performance liquid chromatography, and the concentrations of organic acids were calculated with the use of external standards, and the reproducibility and stability of these measurements were described previously (21).

Immunohistochemical Staining of Ileal Mucosa for Inducible Nitric Oxide Synthase (iNOS). In a separate series of experiments, the iNOS expression on ileum was determined by immunohistochemistry. At 3-hour study period, three rats in each study group with three sham rats were anesthetized, and terminal ileum was excised, immediately frozen in OCT compound (Tissue-Tek; Sakura Finetek Japan, Tokyo, Japan), and then sectioned into 8-µm square. Tissue sections were fixed with 10% neutral buffered formalin for 10 minutes, and washed with Tris buffer solution. They

were treated with Protein Block (Dako, Glostrup, Denmark) for 10 minutes, and incubated with 2 $\mu\text{g}/\text{mL}$ anti-mouse iNOS rabbit polyclonal antibody (Wako Pure Chemical Industry, Osaka, Japan) at 4°C overnight, and washed with Tris buffer solution. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30 minutes. They were treated with Biotin blocking system (Dako) and incubated with biotin-conjugated goat anti-rabbit immunoglobulin (Dako) diluted 1:600, for 30 minutes at reverse transcription. After washing with Tris buffer solution, they were treated with peroxidase-conjugated streptavidin (Nichirei Bioscience, Tokyo, Japan) for 5 minutes. Peroxidase activity was visualized by diaminobenzidine. The sections were counterstained with Mayer's Hematoxylin (Mutoh Chemical, Tokyo, Japan), dehydrated, and then mounted with Malinol (Mutoh). Ten images per each sample were randomly photographed using a microscope attached modular photomicrographic system (Nikon Eclipse TS 100, Nikon, Tokyo). The immunostaining area of the ileum was measured using computer software (NIH image 1.63 software, National Institutes of Health, Bethesda, MD) in a blinded manner (22), and the

ratio of this area to all field of the image was determined as the expression density of iNOS.

Biochemical Analyses. Arterial blood at 3-hour study period was centrifuged at 2500 rpm for 10 minutes at 4°C, and then stored at -80°C for measurements of insulin, cytokines, and NOx. Plasma insulin concentration was measured in duplicate with a specific enzyme-linked immunosorbent assay method using commercially available enzyme-linked immunosorbent assay kit (Mercodia AB, Uppsala, Sweden), which showed cross-reactivity with human insulin. TNF- α and interleukin (IL)-1 β were measured in duplicate by enzyme-linked immunosorbent assay using commercially available kits (Immunoassay Kit, Biosource International, CA). Briefly, after incubation in immobilized antibody and a biotinylated antibody specific for each cytokine, streptavidine-peroxidase is added. This binds to the biotinylated antibody to complete the four-member sandwich. Then, a substrate solution is added, which is acted on by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of each cytokine. NO release was assessed by the determination of plasma NO metabolites (nitrate and nitrite; NOx) by colorimetric assay using the enzyme nitrate reductase (Oxford Biomedical Research Oxford, MI). The intensity was measured using a plate analyzer (ETY-3A, Toyosokki, Tokyo, Japan).

Statistical Analyses. Data were expressed as mean \pm sd unless otherwise specified. Data obtained at various periods were analyzed by two-way analysis of variance with repeated measures using a statistical software package of SPSS/15.0J for Windows (SPSS Inc, Chicago, IL). One-way analysis of variance was applied to examine the data obtained at one study period such as portal FD4, cytokines, and blood gas analyses. Kruskal-Wallis test was used to examine the nonparametric data such as intestinal microbes. *Post hoc* test was made by using Tukey's test. Values of $p < 0.05$ were considered statistically significant.

RESULTS

All animals in both Study protocol 1 and 2 survived for 3-hour study periods.

Study Protocol 1

Changes of Systemic Hemodynamics, Blood Glucose, and Insulin Concentrations. At the baseline (0 hour), the values of mean arterial pressure, heart rate, and blood glucose concentration were not different between the groups. Overall changes of mean arterial pressure and heart rate were trivial throughout the study periods (data not shown), suggesting that the outcome of the present study was unlikely to be dependent on systemic hemodynamics. Blood glucose level in group G was significantly increased at 1 hour and remained higher than the level of 400 mg/dL, which was to some extent higher than we planned (Fig. 1). Those in group S and GI were slightly but significantly elevated at 1 and 2 hour vs. the baseline (0 hour), and became down to the baseline level, i.e., approximately at 100 mg/dL. On the other hand, plasma insulin concentration at 3-hour study period remained low level in group S, but group G and GI showed a marked increase ($6.2 \pm 4.7 \mu\text{g}/\text{L}$ vs. $124.1 \pm 13.4 \mu\text{g}/\text{L}$ and $112.7 \pm 1.0 \mu\text{g}/\text{L}$, respectively; $p < 0.001$). Because of necessary blood sampling limitation, we did not assess the changes of plasma insulin levels during the 3-hour study period. In all sham rats, plasma insulin level was undetectable, i.e., less than 3 $\mu\text{g}/\text{L}$. Collectively, under similar extent of hyperinsulinemia developed, the animals in group G and GI showed stable hyperglycemia and normoglycemia, respectively, for 3-hour study period.

Arterial blood gas analyses at 3 hours after LPS injection showed that arterial pH in all groups were slight metabolic acidosis but were basically compensated well by respiratory alkalosis (Table 1). However, arterial lactate level in group G showed a significant elevation compared with group S and GI. Serum osmolarity, calculated by the standard formula including the values of plasma sodium ion, glucose and urea nitrogen levels, stayed within normal ranges at 3-hour study period in all study groups.

Gut Mucosal Permeability, Cytokines, and NO. Plasma FD4 concentration showed a marked increase in group G compared with the other two groups (Fig. 2). Because portal FD4 concentration in group S was slightly higher than normal value, usually being less than 0.15-mg/mg protein in rats, hyperglycemia augmented gut mucosal permeability which was already elevated by endotoxin injection. Arterial concentration of FD4 showed the similar results as portal levels (data not shown). Simultaneously, arterial concen-




Figure 1. Changes of blood glucose concentrations during the 3-hour study period in endotoxemic rats treated with saline, glucose, and glucose mixed with insulin solutions. Values are expressed as means \pm sd. Group S (n = 6) = saline alone, group G (n = 7) = 40% glucose solution, and group GI (n = 8) = 10% glucose mixed with insulin solution. Significance * $p < 0.01$ vs. group S and GI, $†p < 0.05$, $‡p < 0.01$ vs. 0 hour.

Table 1. Arterial blood gas and lactate levels in endotoxemic rats after 3 hr-infusion of saline, glucose, and glucose mixed with insulin solutions

	Group S (n = 6)	Group G (n = 7)	Group GI (n = 8)
pH	7.43 \pm 0.06	7.35 \pm 0.04 ^a	7.45 \pm 0.07 ^c
PaO ₂ (mm Hg)	99 \pm 9	100 \pm 12	98 \pm 20
PaCO ₂ (mm Hg)	27.3 \pm 3.4	26.0 \pm 4.8	27.3 \pm 6.4
Base excess	-6.3 \pm 1.4	-9.9 \pm 2.5	-5.8 \pm 3.1 ^c
Lactate (mmol/L)	1.6 \pm 0.3	4.7 \pm 0.6 ^b	2.4 \pm 0.5 ^{a,d}
Osmolarity (mOsm/L)	287 \pm 2	293 \pm 5	289 \pm 5

Data were expressed as mean \pm SD.

Group S, saline alone; Group G, 40% glucose solution; Group GI, 10% glucose solution mixed with insulin. Significance: ^a $p < 0.05$, ^b $p < 0.01$ vs. Group S, ^c $p < 0.05$, ^d $p < 0.01$ vs. Group G.




Figure 2. Plasma concentrations of fluorescence-conjugated dextran (FD4), tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), and nitric oxide metabolites (NOx) at 3-hour study period in endotoxemic rats treated with saline, glucose, and glucose mixed with insulin solutions. Values are expressed as means \pm SD. Group S (n = 6) = saline alone, group G (n = 7) = 40% glucose solution, group GI (n = 8) = 10% glucose mixed with insulin solution. Significance: * p < 0.05 vs. group S and GI, # p < 0.05 vs. group S.




Figure 3. Representative micrographs of immunohistochemical staining of ileal mucosa for inducible nitric oxide synthase (iNOS) in sham and endotoxemic rats treated with saline, glucose, and glucose mixed with insulin solutions. Positive staining for iNOS is brown. A, A representative immunostaining of ileal mucosa from a Sham rat. B–D, A representative immunostaining of ileal mucosa from a rat in group S, G, and GI, respectively. Note that the density of iNOS expression is apparently augmented vs. the Sham rat but appears to be similar between the LPS-treated groups.

trations of proinflammatory cytokines, TNF- α , and IL-1 β , were significantly elevated in group G vs. group S and GI. On the other hand, plasma concentrations of NOx, considered as a marker of NO production, were similar between the three groups. Weak but constant staining of iNOS was observed in microvilli of mucosal layer in sham-operated rats (Fig. 3A). Compared with the sham, LPS infusion in all study groups increased iNOS expression on the surface of villus epithelial cells and in crypts more intensely as shown in Figure 3, B–D. However, no significant differences of iNOS expression were not found between the three LPS-treated groups (data not

shown), indicating that LPS injection was a dominant factor to iNOS on ileal mucosa independently of blood glucose or insulin level.

Bacterial Microflora and Organic Acids in Gut and Bacteria in MLNs. In sham rats, the majority of intestinal flora consisted of *Clostridium* group and *Bacteroides fragilis* in *Obligate anaerobes*, and *Lactobacillus* and *Enterococcus* in *Facultative microbe* whereas pathogenic microbes such as *Staphylococcus* or *Pseudomonas* remained relatively low level (Table 2). The three study groups showed the similar tendency to the sham, suggesting that LPS injection did not cause significant alterations of intestinal flora for

3-hour periods. Total organic acids dominated by acetic, propionic, and butyric acids in all LPS-treated groups appeared to be depressed vs. the sham group (Table 3). No significant differences were found between the study groups. Simultaneously, pH level in cecal contents was kept higher vs. the sham, but no statistical difference was found between the three study groups.

Total counts of bacteria present in MLNs of group G were significantly higher vs. group S, whereas the former appeared to be higher vs. group GI but it did not reach statistical significance (Fig. 4). No bacteria was found in the MLNs of all animals in group S, whereas the numbers of animals which showed no bacteria in MLNs were 1 in group G and 3 in group GI, respectively.

Study Protocol 2

Roles of TNF- α in Hyperglycemia-Related Gut Barrier Function and Cytokines. The infusion of Y-41654 did not modulate blood glucose levels at 3 hours in both normoglycemia and hyperglycemia (data not shown). Blood gas analyses at 3-hour period were not altered significantly with Y-41654 infusion whereas hyperglycemia group showed mild metabolic acidosis with a slight but significant elevation of arterial lactate (Table 4).

Plasma FD4 concentration, a marker of gut mucosal permeability, was not altered by treatment with a TACE inhibitor in normoglycemia whereas hyperglycemia-augmented mucosal permeability was significantly reduced by inhibiting TACE activity (Fig. 5A). Figure 5B shows that TACE inhibitor treatment significantly depressed the production of TNF- α , which was excessively discharged by endotoxin injection, in normoglycemia, and simultaneously did reduce the excessive discharges of TNF- α in hyperglycemia. Figure 5C shows that TACE inhibitor treatment did not significantly modulate IL-1 β discharges in either normoglycemia or hyperglycemia group. NOx levels were not different between these four study groups (Fig. 5D).

DISCUSSION

The present study demonstrates that hyperglycemia augments endotoxin-induced gut barrier dysfunction, subsequently inducing bacterial translocation into MLNs, and concurrently excessive production of proinflammatory cytokines such as TNF- α and IL-1 β . The regulation of blood glucose level with insulin infusion ameliorates such dysfunction of gut mucosal barrier in en-

Table 2. Intestinal flora in sham or endotoxemic rats after 3 hr-infusion of saline, glucose, and glucose mixed with insulin solutions

	Group S (n = 6)	Group G (n = 7)	Group GI (n = 8)	Sham (n = 4)
<i>Obligate anaerobes</i>				
<i>Clostridium leptum</i> subgroup	9.1 ± 0.6	8.7 ± 1.3	9.6 ± 0.2	9.7 ± 0.4
<i>Clostridium coccooides</i> group	9.9 ± 0.7	9.6 ± 1.3	10.3 ± 0.3	10.3 ± 0.4
<i>Bacteroides fragilis</i> group	9.3 ± 0.8	8.7 ± 1.4	9.8 ± 0.4	9.8 ± 0.3
<i>Bifidobacterium</i>	7.9 ± 0.8	7.9 ± 1.4	8.3 ± 0.6	8.8 ± 0.4
<i>Atopobium cluster</i>	8.1 ± 0.5	7.8 ± 1.2	8.4 ± 0.2	8.2 ± 0.2
<i>Prevotella</i>	9.0 ± 0.7	8.4 ± 1.2	9.5 ± 0.2	9.4 ± 0.3
<i>Facultative anaerobes and aerobes</i>				
<i>Lactobacillus</i>	9.8 ± 0.6	9.6 ± 0.9	10.2 ± 0.3	10.1 ± 0.4
<i>Enterobacteriaceae</i>	7.1 ± 1.1	6.1 ± 1.0	7.1 ± 0.6	6.4 ± 0.7
<i>Enterococcus</i>	8.4 ± 0.8	8.1 ± 0.7	8.3 ± 0.3	8.4 ± 0.1
<i>Staphylococcus</i>	6.0 ± 0.9	5.7 ± 0.9	6.1 ± 0.8	6.1 ± 0.2
<i>Pseudomonas</i>	< 2.4	< 2.4	< 2.4	< 2.4
Total microbes	10.3 ± 0.6	10.2 ± 0.3	10.8 ± 0.1	10.8 ± 0.1

Data were expressed as mean ± SD (bacteria/g-intestinal contents).

Group S, saline alone; Group G, 40% glucose solution; Group GI, 10% glucose solution mixed with insulin; Sham, saline without endotoxin injection.

No significant differences of intestinal microflora were found between the groups.

Table 3. Organic acids and pH of cecal contents in endotoxemic rats after 3 hr-infusion of saline, glucose, and glucose mixed with insulin solutions

	Group S (n = 6)	Group G (n = 7)	Group GI (n = 8)	Sham (n = 4)
Total organic acid	57.8 ± 18.8	66.5 ± 19.8	65.9 ± 21.9	76.6 ± 23.1
Acetic acid	34.1 ± 7.6	37.6 ± 8.4	38.6 ± 10.9	47.7 ± 15.9
Propionic acid	11.8 ± 2.5	12.6 ± 4.7	12.1 ± 5.0	14.1 ± 5.1
Butyric acid	4.6 ± 2.4	5.7 ± 3.0	6.9 ± 2.8	11.2 ± 1.2
Succinic acid	1.5 ± 1.0	1.3 ± 0.7	1.1 ± 0.5	1.3 ± 0.4
Lactic acid	5.9 ± 4.5	7.7 ± 5.5	7.1 ± 5.1	2.4 ± 1.7
Formic acid	0	0	0.2 ± 0.4	0.1 ± 0.5
Isovaleric acid	2.4 ± 0.4	2.3 ± 0.3	2.4 ± 0.5	0
Valeric acid	1.6 ± 0.5	1.6 ± 0.3	1.1 ± 0.1	0
pH	7.37 ± 0.44	7.35 ± 0.53	7.41 ± 0.39	7.22 ± 0.29

Data were expressed as mean ± SD.

Organic acids (μmol/g-intestinal contents).

Group S, saline alone; Group G, 40% glucose solution; Group GI, 40% glucose solution mixed with insulin solution; Sham, saline without endotoxin injection.

There were no significant differences in all organic acids and pH between the study groups.

dotoxemia, accompanied by inhibition of excessive production of proinflammatory cytokines. Although previous study demonstrated that increased insulin administration is positively associated with poor outcome regardless of the prevailing blood glucose level (23), the present study showed that hyperglycemia rather than plasma insulin level played a significant role in the regulation of gut mucosal permeability, possibly associated with the modality and mortality in critically ill. Additionally, inhibiting the conversion of membrane-bound to soluble TNF-α plays a key role in the hyperglycemia-augmented gut barrier dysfunction evoked by endotoxin. Collectively, these findings indicate that control of blood glucose in critically ill is of great consequence in the preservation of gut barrier function through TNF-α discharge-dependent mechanisms.

In the present study, abnormal overgrowth and/or distribution of bacterial microflora in gut lumen were not found but pathogenic bacteria were translocated into the MLNs only in group G. Thus, hyperglycemia did not modulate microflora but facilitate the translocation of pathogenic microbes through increased mucosal permeability of gut. Because the transcription of rRNA and production of ribosome are extremely greater in viable vs. nonviable bacteria, the total amount of rRNA produced by nonviable bacteria could be ignored (24). Previous study clearly demonstrated that reverse transcription-quantitative polymerase chain reaction, highly correlated with conventional culture, was a valuable method to assess the number of viable microbes by targeting rRNA from bacteria (20). Another impor-

(bacteria / g-tissue)



Figure 4. Total bacterial counts in mesenteric lymph nodes of endotoxemic rats treated with saline, glucose, and glucose mixed with insulin solutions. Group S (n = 6) = saline alone, group G (n = 7) = 40% glucose solution, group GI (n = 8) = 10% glucose mixed with insulin solution. The box represents the 25th to 75th percentiles in which black line is the median. The extended bars represent the 10th to 90th percentiles. Significance: *p < 0.05 vs. group S.

tant finding of the present study was to show that total organic acids in cecal contents were apparently reduced in all LPS-treated groups vs. the Sham animals. As energy substrates, short-chain fatty acids such as butyric, propionic, and acetic acids produced by intestinal microflora contributed to the preservation of gut homeostasis and proliferation of epithelial injury (25, 26). On the other hand, intestinal pH, modulating intraluminal microflora, absorption ability, and activity of digestive enzymes (27), was not affected by blood glucose or insulin level, suggesting that intraluminal environments were not directly associated with hyperglycemia or hyperinsulinemia under endotoxemia. Given these findings, at least for 3-hour examination period, LPS injection, rather than the changes of blood glucose or insulin level, deteriorates the production pathway of organic acids by intestinal microflora, and subsequently modulates mucosal function. However, we need to be cautious that bacterial analysis of stool is a complicated procedure and the results might be depending on the intestinal segment as described previously (28).

Several mechanisms to regulate gut barrier function have been proposed to date. Among them, endogenous production of NO plays the most important role in the modulation of gut permeability (11, 29) although NO is known to have paradoxical effects on gastrointestinal perfusion and integrity depending on its concentrations (30). In sepsis, up-regulation of iNOS expression leads to a prolonged increase of NOx in tissue and plasma levels (31). Indeed, expression of iNOS on mucosal layer was apparently augmented in all LPS-treated animals vs. the sham, whereas we were able to find neither significant alter-

Table 4. Arterial blood gas and lactate levels in endotoxemic rats after 3 hr-infusion of saline or glucose solution, with or without tumor necrosis factor converting enzyme (TACE) inhibitor

	Group S (n = 8)	Group ST (n = 9)	Group G (n = 8)	Group GT (n = 7)
pH	7.43 ± 0.03	7.45 ± 0.04	7.37 ± 0.05 ^{a,b}	7.40 ± 0.07
PaO ₂ (mmHg)	85 ± 7	87 ± 7	95 ± 7	88 ± 8
PaCO ₂ (mmHg)	29 ± 2	28 ± 5	23 ± 5	25 ± 6
Base excess	-5 ± 2	-4 ± 2	-12 ± 3 ^{a,b}	-10 ± 3 ^{a,b}
Lactate (mmol/L)	1.3 ± 0.5	1.1 ± 0.2	5.1 ± 0.8 ^{a,b}	4.2 ± 1.1 ^{a,b}

Data were expressed as mean ± SD.

Group S, saline alone; Group ST, saline with TACE inhibitor; Group G, 40% glucose solution alone; Group GT, 40% glucose solution with TACE inhibitor.

Significance: ^a*p* < 0.05 vs. Group S; ^b*p* < 0.05 vs. Group ST.




Figure 5. Plasma concentrations of fluorescence-conjugated dextran (FD4), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and nitric oxide metabolites (NOx) in endotoxemic rats after 3-hour infusion of saline or glucose solution with or without tumor necrosis factor converting enzyme (TACE) inhibitor. Group S (n = 8) = saline alone, group ST (n = 9) = saline with TACE inhibitor, group G (n = 8) = 40% glucose solution alone, group GT (n = 7) = 40% glucose solution with TACE inhibitor. Values are expressed as means ± SD. Significance: **p* < 0.05 vs. group S, #*p* < 0.05 vs. group G.

ations of plasma NOx levels nor intensity of iNOS expression using immunohistochemical study in this hyperglycemia model. Consequently, the local production of iNOS protein on the mucosal layer and plasma NO production is unlikely to regulate hyperglycemia-augmented gut barrier dysfunction evoked by endotoxin. However, recent study showed that circulating NO level did not necessarily reflect regional or local NO availability, and that local NO production was modulated not only by NOS gene transcription but also by other mechanisms such as glycemic control, substrate for NOS availability, and endogenous NOS inhibitors (32). Nevertheless, the possibility that hyperglycemia-induced gut barrier dysfunction is caused by modulating NO bioavailability *in situ* cannot be excluded. As another regulatory factor in gut barrier function, previous studies indicated that TNF played a critical role in *in vivo* and *in vitro* experimental settings (12, 33). For

examples, TNF-α caused the disruption of tight junction in intestinal epithelial cells by up-regulating myosin light chain kinase activity and expression (34), and gut barrier function in patients with Crohn's disease, characterized by permeable epithelial barrier, was restored by anti-TNF treatment using monoclonal antibody (12). In this experiment, we applied a TACE inhibitor which was found to have competitive property against TACE *per se* to inhibit cleavage of membranous TNF-α and release soluble TNF-α, and found that an inhibition of TACE suppressed gut mucosal permeability significantly despite a marked hyperglycemia presented. Thus, soluble TNF-α was apparently engaged as a major factor in the regulation of gut barrier dysfunction induced by hyperglycemia in this endotoxemic animal. However, the present study was unable to answer whether the presence of membrane-bound TNF-α, characterized by potent protective property against lethal

dose of LPS (35), or limited amount of soluble TNF-α is a key factor to minimize hyperglycemia-augmented gut barrier dysfunction. On the other hand, given the finding that IL-1β was also significantly discharged in group G as shown in Figure 2, IL-1β could be another contributor to the hyperglycemia-augmented gut barrier dysfunction. Indeed, recent study demonstrated that IL-1β increased gut epithelial tight junction permeability possibly through the activation of nuclear factor κB (36). Further study is warranted to examine the roles of IL-1β as well as biological activity of TACE in hyperglycemia-elicited gut barrier dysfunction.

There were several issues which should be resolved to justify our model. With a marked elevation of blood glucose, high serum osmolarity possibly caused by hyperglycemic state could modulate the outcome of this study. However, serum osmolarity calculated using a standard formula showed no significant differences between the groups (Table 1). Second, we applied low-dose endotoxin injection to mimic critically ill state. Under this dose of endotoxin injection with fluid therapy, mean arterial pressure remained constant and gut mucosal permeability was increased slightly but significantly at 3 hours in our pilot study. Some may argue that the range of hyperglycemia in this model might be too high to represent clinical situation. In our pilot study, we were unable to keep 200–300 mg/dL of blood glucose for 3- to 5-hour study period by using 10% or 20% glucose solution in this endotoxemic rat model possibly because of endogenous insulin discharges. Although the validity of clinical relevance in this hyperglycemia model may become lesser, we were obliged to choose 40% glucose solution in group G, and found the reproducibility of stable hyperglycemia and the similar extent of hyperinsulinemia to group GI in this experimental setting. Previous study using burned animal model also showed that a marked hyperglycemia, primarily intended to range between 250 and 350 mg/dL of blood glucose, reached approximately 300–450 mg/dL to be examined (15). It might be occasionally tough to keep this range of hyperglycemia for certain time periods in animal model of critically ill. Third, the 3-hour study period might be too short to be relevant to clinical situations that usually persist for several days. Indeed, we were unable to find significant alterations of gut microflora despite a marked increase of mucosal permeability. Chronic hyperglycemia enhanced production of reactive oxygen species accompanied by attenuation of

antioxidant mechanisms (37), whereas even short term of hyperglycemia could modulate immune function and cytokine production (6, 38). Ling et al (6) demonstrated that 3 hours of hyperglycemia (300–350 mg/dL) increased the discharges of inflammatory cytokines. On the contrary, the present study showed that only 3 hours, being rather realistic in clinical situation as an interval of blood glucose evaluation, was long enough to cause these significant alterations of gut mucosal permeability if excessive hyperglycemia persisted. Fourth, our study design may not allow us to answer the issue which factor, keeping normoglycemia vs. glycemia-independent action of insulin, was significant to ameliorate hyperglycemia-augmented gut barrier dysfunction in endotoxemia as previously reported (15). However, it should be noted that gut barrier function was apparently different between group G and GI, both of which showed the similar level of hyperinsulinemia. In other words, gut barrier dysfunction associated with hyperglycemia was restored, at least, independently of plasma insulin concentration. Finally, we applied an *in vivo* ligated intestinal loop model, characterized by anatomically intact blood supply and drainage as well as autonomic innervation, to evaluate gut mucosal permeability although several limitations were pointed out (39, 40).

In conclusion, hyperglycemia deteriorates endotoxin-induced gut barrier dysfunction which can be restored by keeping normoglycemia with insulin infusion. Among several factors, the modulation of soluble TNF- α discharges plays a significant role to prevent bacterial translocation in critically ill.

REFERENCES

- Marik PE, Raghavan M: Stress-hyperglycemia, insulin and immunomodulation in sepsis. *Intensive Care Med* 2004; 30:748–756
- Krinsley JS: Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc* 2003; 78:1471–1478
- Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001; 345:1359–1367
- Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006; 354:449–461
- Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008; 358:125–139
- Ling PR, Smith RJ, Bistrian BR: Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. *Crit Care Med* 2005; 33:1084–1089
- Brix-Christensen V, Andersen SK, Andersen R, et al: Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: An experimental study in a porcine model. *Anesthesiology* 2004; 100:861–870
- Van den Berghe G, Wouters P, Bouillon R, et al: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. *Crit Care Med* 2003; 31:359–366
- Chen HI, Yeh DY, Liou HL, et al: Insulin attenuates endotoxin-induced acute lung injury in conscious rats. *Crit Care Med* 2006; 34:758–764
- Meakins JL, Marshall JC: The gastrointestinal tract: The motor of multiple organ failure. *Arch Surg* 1986; 121:197–201
- Kubes P: Nitric oxide modulates epithelial permeability in the feline small intestine. *Am J Physiol* 1992; 262:G1138–G1142
- Suenaert P, Bulteel V, Lemmens L, et al: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. *Am J Gastroenterol* 2002; 97:2000–2004
- Esposito K, Nappo F, Marfella R, et al: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. *Circulation* 2002; 106:2067–2072
- Bengmark S: Use of some pre- and pro- and symbiotics in critically ill patients. *Best Pract Res Clin Gastroenterol* 2003; 17:833–848
- Ellger B, Debaveye Y, Vanhorebeek I, et al: Survival benefits of intensive insulin therapy in critical illness: Impact of maintaining normoglycemia versus glycemia-independent actions of insulin. *Diabetes* 2006; 55:1096–1105
- Guo W, Magnotti L, Ding J, et al: Influence of gut microflora on mesenteric cytokine production in rats with hemorrhagic shock. *J Trauma* 2002; 52:1178–1185
- Kosugi S, Morisaki H, Satoh T, et al: Epidural analgesia prevents endotoxin-induced gut mucosal injury in rabbits. *Anesth Analg* 2005; 101:265–272
- Shimizu K, Ogura H, Asahara T, et al: Altered gut flora and environment in patients with severe SIRS. *J Trauma* 2006; 60:126–133
- Jansen GJ, Wildeboer-Veloo AC, Tonk RH, et al: Development and validation of an automated, microscopy-based method for enumeration of groups of intestinal bacteria. *J Microbiol Methods* 1999; 37:215–221
- Matsuda K, Tsuji H, Asahara T, et al: Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. *Appl Environ Microbiol* 2007; 73:32–39
- Kikuchi H, Yajima T: Correlation between water-holding capacity of different types of cellulose in vitro and gastrointestinal retention time in vivo of rats. *J Sci Food Agr* 1992; 60:139–146
- Suzuki T, Morisaki H, Serita R, et al: Infusion of the β -adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. *Crit Care Med* 2005; 33:2294–2301
- Finney S, Zekveld C, Elia A, et al: Glucose control and mortality in critically ill patients. *JAMA* 2003; 290:2041–2047
- Condon C, Squires C, Squires L: Control of rRNA transcription in *Escherichia coli*. *Microbiol Rev* 1995; 59:623–645
- Macfarlane S, Macfarlane G: Regulation of short-chain fatty acid production. *Proc Nutr Soc* 2003; 62:67–72
- Blottiere B, Buechaer B, Galmiche J, et al: Molecular analyses of the effect of short-chain fatty acids on intestinal cell proliferation. *Proc Nutr Soc* 2003; 62:101–106
- Fallingborg J: Intraluminal pH of the human gastrointestinal tract. *Dan Med Bull* 1999; 46:183–196
- Schneider SM, Le Gall P, Girard-Popau F, et al: Total artificial nutrition is associated with major changes in the fecal flora. *Eur J Nutr* 2000; 39:248–255
- Xu DZ, Lu Q, Deitch EA: Nitric oxide impairs intestinal barrier function. *Shock* 2002; 17:139–145
- Lamarque D, Whittle BJ: Increase in gastric intramucosal hydrogen ion concentrations following endotoxin challenge in the rat and the actions of nitric oxide synthase inhibitors. *Clin Exper Pharmacol Physiol* 2001; 28:164–168
- Gomez-Jimenez J, Salgado A, Mourelle M, et al: L-arginine: Nitric oxide pathway in endotoxemia and human septic shock. *Crit Care Med* 1995; 23:253–258
- Ellger B, Langouche L, Richir M, et al: Modulation of regional nitric oxide metabolism: Blood glucose control or insulin? *Intensive Care Med* 2008; 34:1525–1533
- Zolotarevsky Y, Hecht G, Koutsouris A, et al: A membrane-permeant peptide that inhibits MLC kinase restores barrier function in vitro models of intestinal disease. *Gastroenterology* 2002; 123:163–172
- Ye D, Ma I, Ma TY: Molecular mechanism of tumor necrosis factor—A modulation of intestinal epithelial tight junction barrier. *Am J Physiol* 2006; 290:G496–G504
- Mohler KM, Sleath PR, Fitzner JN, et al: Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. *Nature* 1994; 370:218–220
- Al-Sadi RM, Ma TY: IL-1 β causes an increase in intestinal epithelial tight junction permeability. *J Immunol* 2007; 178:4641–4649
- Lelkes E, Unsworth BR, Lelkes PI: Reactive oxygen species, apoptosis and altered NGF-induced signaling in PC12 pheochromocytoma cells cultured in elevated glucose: An in vitro cellular model for diabetic neuropathy. *Neurotox Res* 2001; 3:189–203
- Kwoun MO, Ling PR, Lydon E, et al: Immunologic effects of acute hyperglycemia in nondiabetic rats. *J Parenter Enteral Nutr* 1997; 21:91–95
- Tagesson C, Sjö Dahl R, Thoren B: Passage of molecules through the wall of the gastrointestinal tract I. A simple experimental model. *Scand J Gastroenterol* 1978; 13:519–524
- Otamiri T, Sjö Dahl R, Tagesson C: Lysophosphatidylcholine potentiates the increase in mucosal permeability after small-intestinal ischaemia. *Scand J Gastroenterol* 1986; 21:1131–1136

ステントグラフト内挿術後の腹部大動脈瘤に 対し人工血管置換術を施行した1例

<Brief Report>

Open Abdominal Aortic Aneurysm Repair after Endovascular Stent Grafting

Yasuo Suzuki¹, Jungo Kato¹,
Komei Ai¹, Kiyoshi Moriyama¹,
Hideyuki Shimizu² and Junzo Takeda¹
Department of Anesthesiology¹,
Department of Cardiovascular Surgery²,
School of Medicine, Keio University

An 87-year-old woman with interstitial pneumonia and renal dysfunction had persistent type II endoleak after endovascular stent grafting for abdominal aortic aneurysm (AAA). Four years after the stent grafting, she underwent open AAA repair under general anesthesia. The operation was successfully performed and the patient was discharged 2 weeks after the operation. Open AAA repair after stent grafting is expected to increase in the future, and anesthesiologists need to take account the risks not only arising from patients but also from surgical procedure.

(*J Clin Anesth (Jpn)* 2009; 33: 1049-50)

Key words : Endovascular stent grafting,
Open abdominal aortic aneurysm repair,
Endoleak

腹部大動脈瘤 (abdominal aortic aneurysm: AAA) に対するステントグラフト手術は、欧米では AAA 治療の約 50% を占め、本邦でも頻度は増加している¹⁾。大動脈ステントグラフト内挿術施行 4 年後に、人工血管置換術を施行した症例を経験した。

症 例

87 歳の女性。身長 153 cm、体重 41 kg。1 歳時に腎膿瘍で左腎を摘出した。間質性肺炎を合併していたため、83 歳時に AAA に対し Y 型ステントグラフト内挿術を施行した。術後 3 カ月頃より endoleak type

キーワード：ステントグラフト，人工血管置換術，
エンドリーク

II を疑われ外来で経過観察していたが、瘤の増大傾向を認め今回開腹手術を予定した。

術前検査でクレアチニンクリアランスは 52 mL/min と低下し、胸部 X 線写真で両側肺野の透過性が低下していた。Hugh-Jones 分類は I 度で、呼吸機能検査で 1 秒率 76%、1 秒量 1.21 L と閉塞性肺障害を認めた。心電図で完全右脚ブロック、左脚前枝ブロックを認めたが、経胸壁心エコーで心機能は良好とされた。

腹部 CT 検査では、腎動脈分岐後約 1.5 cm にステントグラフトの上端が存在し、瘤の最大径は 63×53 mm、腰動脈から endoleak が疑われた (Fig. 1)。開腹しての Y グラフト置換術を予定したが、瘤周囲の癒着、大動脈遮断が腎動脈分岐部より中枢側になる可能性、術野でステントグラフトの位置確認に難渋する可能性、血管内膜損傷の可能性など、手術操作が困難となることが予想された。




Fig. 1 Type II endoleak from lumbar artery.

麻酔はプロポフォール+レミフェンタニルによる静脈麻酔に硬膜外麻酔を併用し、心拍出量モニタリングのためフロートラックセンサー[®]およびプリセップカテーテル[®]を用いた。心係数および中心静脈血酸素飽和度は術中から術後 1 日まで計測された。瘤周囲の




Fig. 2 Type II endoleak from lumbar artery.

癒着剝離は容易で、大動脈遮断はステントグラフトを含めず腎動脈分岐下で可能であった。瘤を切開したところ腰動脈からの血液流入を認めた。ステントグラフトは無事摘出され (Fig. 2)、同部位に Y 型人工血管を留置した。手術時間は 4 時間、麻酔時間は 5 時間 35 分で、出血量は 1,500 mL、尿量は 700 mL、輸液量は 6,050 mL、輸血量は 780 mL、自己回収血輸血は 750 mL であった。術中循環動態は安定し、手術室内で抜管後集中治療室へ入室した。心係数は術中 1.9~2.8 L/min/m²、術後 2.8~3.3 L/min/m²、中心静脈血酸素飽和度は術中 71~90%、術後 73~83% に保たれた。術後経過は良好で 2 週間後に退院した。

考 察

AAA に対するステントグラフトを用いた治療は、本邦では 2002 年にステントグラフト内挿術として保険適用となり、2006 年より Zenith AAA endovascular graft (Cook 社) が治療用デバイスとして保険適用となった。本邦での使用頻度は上昇しており、AAA 治療全体の 40% を占める見込みである¹⁾。ステントグラフト内挿術の術後に 1.8~28% で人工血管置換術が必要になるとの報告があり²⁻⁴⁾、endoleak, endotension, migration, graft disconnection により大動脈瘤の破裂をきたした報告もある⁵⁾。本邦でもステントグラフト術後の人工血管置換術についての報告が散見される⁶⁻⁹⁾。

ステントグラフト内挿術後の人工血管置換術は、患者の術前リスクが高いことに加え、手術操作自体が難航することがある⁹⁾。本症例でも、患者は高齢な上

に腎機能および肺機能が低下しており、また、手術が難航する可能性が考えられた。ステントグラフト抜去時には、内膜損傷・大動脈解離や血栓塞栓症により血栓除去、腎動脈再建、下肢バイパス術などの追加手術が必要となるとの報告がある²⁾。ステントグラフト挿入術の術中術後に種々の理由で緊急人工血管置換術が必要となった症例では、多臓器不全、心合併症、呼吸器不全による死亡率が高いことが報告されている³⁾。

本邦で今後、ステントグラフト後の AAA に対する開腹術が増加すると思われる。その際は患者の術前リスクが高く、手術も難航する可能性が高いため、麻酔科医も術前からその対策を検討する必要がある。

文 献

- 1) 四津良平, 石丸 新, 加藤雅明, 他: 大動脈ステントグラフト内挿術の合併症とその対策. CIRCULATION Up-to-Date 2008; 3: 352-61
- 2) Tiesenhausen K, Hessinger M, Konstantiniuk P, et al: Surgical conversion of abdominal aortic stent-grafts. Eur J Vasc Endovasc Surg 2006; 31: 36-41
- 3) Cuypers PWM, Laheij RJF, Buth J, et al: Which factors increase the risk of conversion to open surgery following endovascular abdominal aortic aneurysm repair? Eur J Vasc Endovasc Surg 2000; 20: 183-89
- 4) Biebl M, Hakaim A, Oldenburg W, et al: Midterm results of a single-center experience with commercially available devices for endovascular aneurysm repair. Mt Sinai J Med 2005; 72: 127-35
- 5) Schlösser FJ, Gusberg RJ, Dardik A, et al: Aneurysm rupture after EVAR. Eur J Vasc Endovasc Surg 2009; 37-1: 15-22
- 6) 伊藤寿朗, 川原田修義, 栗本義彦, 他: 腹部大動脈瘤ステントグラフト内挿術後同部位に人工血管置換術を施行した 2 例. 日心外会誌 2007; 36: 141-4
- 7) 渡部芳子, 石丸 新, 川口 聡, 他: ステントグラフト内挿術後の人工血管置換術に工夫を要した腹部大動脈瘤の 1 例. 日血外会誌 2005; 14: 14-34
- 8) 一関一行, 伊東和雄, 棟方 護, 他: ステントグラフト内挿術後再破裂をきたした破裂性動脈瘤の 2 例. 日心外会誌 2007; 33: 34-7
- 9) 秋田淳年, 栃井将人, 星野 竜, 他: ステントグラフト治療 5 年後の破裂に対して外科手術で救命し得た腹部大動脈瘤の 1 例. 日血外会誌 2007; 16: 55-8

* * *

Can Mixed Venous Hemoglobin Oxygen Saturation Be Estimated Using a NICO Monitor?

Yoshifumi Kotake, MD, PhD*

Takashige Yamada, MD†

Hiromasu Nagata, MD†

Takeshi Suzuki, MD, PhD†

Junzo Takeda, MD, PhD†

BACKGROUND: We hypothesized that mixed venous hemoglobin oxygen saturation (SvO₂) can be estimated by calculation from CO₂ production, cardiac output, and arterial oxygen saturation measured using a noninvasive cardiac output (NICO) monitor (Novamatrix-Respironics, Wallingford, CT).

METHODS: Twenty-three patients undergoing aortic aneurysm repair underwent SvO₂ monitoring using a pulmonary artery catheter and cardiac output monitoring using a NICO monitor. The estimated SvO₂ value calculated from NICO monitor-derived values was compared with the SvO₂ value measured using a pulmonary artery catheter. The accuracy of this estimation was analyzed with Bland-Altman method. The ability of this estimation to track the change of SvO₂ was also evaluated using correlation analysis to compare the changes of estimated SvO₂ and measured SvO₂.

RESULTS: The bias ± limits of agreement of the estimated SvO₂ against measured SvO₂ was -2.1% ± 11.2%. The change of estimated SvO₂ was modestly correlated with the change of measured SvO₂.

CONCLUSIONS: SvO₂ derived from the values measured by the NICO monitor cannot be used interchangeably with the values measured spectrophotometrically using the pulmonary artery catheter. More refinement is required to obtain more reliable estimate of SvO₂ less invasively. However, large changes of SvO₂ may be detected with this method and can be used as a precautionary sign when the balance between oxygen supply and demand is compromised without inserting a central venous catheter.

(Anesth Analg 2009;109:119-23)

Mixed venous oxygen saturation (SvO₂) or its surrogate, central venous oxygen saturation (ScvO₂), is used to assess the oxygen supply-demand relationship.¹⁻³ However, central venous access is required to measure these values, which carries some risk to the patient. Theoretically, SvO₂ can be calculated using cardiac output (CO), the concentration of oxygen saturated hemoglobin (Hb), and oxygen consumption (VO₂).⁴ If the relationship between VO₂ and CO₂ production (VCO₂) remains stable during anesthesia, SvO₂ can be estimated with CO, VCO₂, and Hb concentration and its arterial oxygen saturation. Because CO, VCO₂,

and Spo₂ are continuously monitored with a noninvasive cardiac output (NICO) monitor (Respironics-Novametrics, Wallingford, CT), we hypothesized that SvO₂ could be mathematically estimated using these NICO-derived parameters and the Hb concentration.^{5,6} The purpose of this prospective study was to assess the accuracy of estimating SvO₂ using the NICO monitor in anesthetized, ventilated patients.

METHODS

The study protocol was approved by the IRB of Keio University, and written informed consent was obtained from the participants. Twenty-three patients undergoing elective infrarenal aortic reconstruction were enrolled in this prospective, observational study. Patients' lungs were mechanically ventilated with a tidal volume of 10 mL/kg, and the respiratory rate was adjusted to maintain normocapnia. CO, VCO₂, and Spo₂ were continuously monitored with a NICO monitor (Ver. 5.2, Novamatrix-Respironics, Wallingford, CT). The NICO sensor was placed between the heat and moisture exchanger and the Y-piece of the respiratory circuit, and the length of the rebreathing circuit was adjusted to maintain optimal condition. NICO-derived CO, VCO₂, and Spo₂ values were downloaded to a personal computer and later used for calculation. For CO, results of average mode (CO-a)

From the *Department of Anesthesiology, Toho University Medical Center Ohmori Hospital; and †Department of Anesthesiology, School of Medicine, Keio University, Tokyo, Japan.

Accepted for publication January 21, 2009.

Supported by Intramural Department Sources Only.

Yoshifumi Kotake is a paid consultant of Edwards Lifesciences. All other authors have no conflict of interest to disclose.

Reprints will not be available from the author.

Address correspondence to Yoshifumi Kotake, MD, PhD, Department of Anesthesiology, Toho University Medical Center Ohmori Hospital, 6-11-1, Ohmori-nishi, Ohta, Tokyo 143-8541, Japan. Address e-mail to ykotake@med.toho-u.ac.jp.

Copyright © 2009 International Anesthesia Research Society

DOI: 10.1213/ane.0b013e3181a85c22

were used. An 8Fr pulmonary artery catheter (PAC) equipped with continuous CO measurement and venous oximetry functions (746HF8, Edwards Lifesciences, Irvine, CA) was inserted via the right internal jugular vein. CO and SvO₂ were continuously monitored after the SvO₂ was calibrated using an *in vivo* method of measuring mixed venous blood with a CO-oximeter (Stat M Profile, Nova Biochemicals, Waltham, MA). The averaged SvO₂ during a 3-min rebreathing cycle of the NICO monitor was used as a representative measured SvO₂ value. Hb was measured every 60 min by the same blood gas analyzer. Between these measurements, Hb concentration was assumed to change linearly between these measurements, and these interpolated values were used for subsequent calculations.

Estimated SvO₂ is defined by following formula (see appendix):

$$\text{Estimated SvO}_2 = \text{SpO}_2$$

$$\frac{\text{VCO}_2 \text{ (mL/min)}/0.85}{1.36 \times \text{Hb (g/dL)} \times \text{CO-a (L/min)} \times 0.1}$$

Data were excluded from the analysis when the signal quality indicator was reported as 3 or 4 by the Vigilance II monitor. Data obtained during the first 20 min after cross-clamp release were also excluded from the analysis, because venous blood returned from infrarenal lesions upon the release of cross-clamp was significantly hypoxemic and caused independent effects on SvO₂. Additionally, CO was measured several times during the surgery with intermittent bolus thermodilution method (ICO). The estimated SvO₂ value with ICO was then calculated by substituting the ICO value in the above formula to analyze the possible contribution of measurement error with NICO-derived CO.

Data are expressed as mean \pm SD and were statistically analyzed using the Prism software (ver 4, Graphpad, San Diego, CA). Bland-Altman analysis was initially applied to the individual data to describe the agreement between estimated SvO₂ and measured SvO₂. Thereafter, the data were pooled to derive overall bias \pm limits of agreement (2SD of difference) in all the measurement pairs. A correction was made according to the literature because multiple observations from individuals were used in this analysis.^{7,8} To assess how the estimated SvO₂ tracks the changes of measured SvO₂, the relationship between the change of estimated SvO₂ between the two consecutive measurement against the incidental change of measured SvO₂ was analyzed with Pearson's correlation coefficient and regression analysis according to a previous report.⁹

RESULTS

Twenty male and three female patients participated in this study. The age, height, and weight of these




Figure 1. Distribution of bias between estimated mixed venous hemoglobin oxygen saturation (SvO₂) and measured SvO₂ from an individual subject. *x* axis denotes ranges of the bias from an individual subject. *y* axis denotes number of subjects. Number of the measurement in each subject varies between 45 and 82.




Figure 2. Distribution of precision between estimated mixed venous hemoglobin oxygen saturation (SvO₂) and measured SvO₂ from an individual subject. *x* axis denotes ranges of the limits of agreement from an individual subject. *y* axis denotes number of subjects. Number of the measurement in each subject varies between 45 and 82.

participants were 72 \pm 8 yr old, 164 \pm 6 cm, and 62 \pm 13 kg, respectively. The duration of surgery and of cross-clamp were 266 \pm 54 min and 59 \pm 18 min, respectively. The mean (range) of measured SvO₂ was 78% (44%–94%). One thousand three hundred thirty-three pairs of estimated SvO₂ and measured SvO₂ were included in the analysis. Between 45 and 82 pairs of measurements from each individual were included. The bias and the limits of agreement in each study subjects are summarized in Figures 1 and 2. Figure 3 demonstrates the Bland-Altman plot of all the measurements. The bias \pm limits of agreement of estimated SvO₂ by NICO monitor was $-2.1\% \pm 11.2\%$ against the spectrophotometrically measured SvO₂. Even when the analysis was limited to the hemodynamically stable period, which is arbitrarily defined as CO change was within 2% between 3-min interval, the bias did not significantly change (1172 data points,




Figure 3. Bland-Altman plot of 1333 pairs of estimated and measured mixed venous hemoglobin oxygen saturation (SvO₂). The bias is demonstrated as a solid line, and the limits of agreement (2SD of the difference) are also demonstrated as a dashed line in this figure.




Figure 4. Changes of measured mixed venous hemoglobin oxygen saturation (SvO₂) and estimated SvO₂ between two consecutive measurement cycles. $n = 1265$, solid line denotes regression line: $r^2 = 0.145$, $P < 0.001$, the change of estimated SvO₂ = $0.39 \times$ the change of measured SvO₂ - 0.06 .

bias \pm limits of agreement: $-2.1\% \pm 11.0\%$). CO was determined with bolus thermodilution 120 times in these subjects. The bias \pm limits of agreement of ICO-derived SvO₂ estimation against measured SvO₂ was $-4.4\% \pm 13.8\%$ and no clear improvement of agreement was demonstrated. The relationship between the change of estimated SvO₂ and the change of measured SvO₂ is summarized in Figure 4. The change of estimated SvO₂ was modestly but significantly correlated with the change of measured SvO₂ between the measurement cycle ($r^2 = 0.145$, $P < 0.001$).

DISCUSSION

This study demonstrated that the bias \pm limits of agreement between the estimated SvO₂ and the measured SvO₂ were $-2.1\% \pm 11.2\%$. This study confirmed that SvO₂ could be reasonably estimated by the

NICO-derived parameters with several assumptions. However, these data indicate that the NICO-derived SvO₂ value cannot be used interchangeably against the SvO₂ value obtained with PAC equipped with oximetry function.

It is intuitively advantageous to objectively assess hemodynamic status with CO. However, the goal of hemodynamic optimization should be to achieve well-balanced oxygen supply and VO₂ instead of a predetermined CO. Based on this perspective, the clinical importance of venous oximetry as a tool to evaluate oxygen supply-demand balance is well established.^{1,2} However, measuring SvO₂ requires PAC insertion, which carries some additional risk over central venous catheterization. Alternatively, ScvO₂ has been used for the same purpose.^{3,10} However, previous reports demonstrated that there was a significant variability between SvO₂ and ScvO₂ and concluded that these two parameters are not interchangeable.^{9,11-13} The differences in regional oxygen extraction, especially the hepatosplanchnic region and central nervous system have been attributed to this significant variability. To assess the balance of oxygen supply and demand less invasively, several attempts have been made to estimate the SvO₂ value without inserting a central venous catheter.¹⁴⁻¹⁶ Alternatively, SvO₂ can be estimated if CO, Hb, SaO₂, and VO₂ are known. As NICO measures CO, Spo₂, and VCO₂, we speculated that SvO₂ could be calculated with reasonable accuracy if Hb and the relationship between VO₂ and VCO₂ were adequately estimated.

We found considerably wide limits of agreement between the estimated SvO₂ and the measured SvO₂. This finding may be attributed to several factors, including the inaccuracy or the temporal delay of one of the measured values incorporated into the formula and several assumptions. First, the accuracy of CO measurement may contribute to a relatively large variation. The NICO monitor has been known to

underestimate the CO in general.^{17,18} Our unpublished analysis demonstrated that the bias \pm limits of agreement of the current version of the NICO monitor was -0.18 ± 1.70 L/min against standard ICO. However, when CO values derived from ICO were used in the same calculation, the limits of agreement remained large. Thus, using a presumably more accurate and instantaneous CO data from ICO failed to increase the accuracy of the estimation of SvO₂. These findings suggest that the inaccuracy of CO data from the NICO monitor cannot fully account for the variability between the estimated and measured SvO₂. Furthermore, the temporal delay of NICO-derived CO after hemodynamic change may also contribute to the wide variability. Although the response time of the NICO monitor has not yet been determined, SvO₂ changes are generally believed to change more rapidly than continuous CO and NICO. Alternatively, the response of SvO₂ to the actual hemodynamic change may be delayed, because the physiological process, such as increasing oxygen extraction in tissues, is involved in this process. These possibilities remain to be evaluated. Second, several assumptions used in this study may contribute to the observed variability. For example, Hb concentration may be a source of error, because it is only determined intermittently and the interpolated value between these measurement was used in this study. However, bias \pm limits of agreement of paired measurements was not significantly improved when the Hb was measured (data not shown). Similarly, using SaO₂ data obtained from blood gas analysis did not improve the accuracy either. Therefore, the Hb concentration or SpO₂ may not be a major source of error. Recently, a device that continuously and percutaneously measures Hb has become available. Thus, with the advance of technology, this issue may be resolved in the future. Using VCO₂ to estimate VO₂ is another potential source of error in this estimation. We used a fixed 0.85 value of the VCO₂/VO₂ ratio to convert VCO₂ to VO₂ throughout this study to make monitoring settings as simple as possible. Although it is intuitively obvious that the ratio may significantly vary in anesthetized patients and critically ill patients, this variability may primarily contribute to the large limits of agreement found in this study. Although measuring VO₂ instead of VCO₂ should improve the accuracy, the precise and continuous determination of VO₂ requires specialized equipment and may substantially compromise the applicability of this method.

It is debatable whether the estimated value of SvO₂ has reasonable accuracy for clinical use. Previous discussions on SvO₂ and its surrogate, ScvO₂, can be used for this purpose. Dueck et al.⁹ investigated the bias and limits of agreement between ScvO₂ and SvO₂ in neurosurgical patients and found the largest 95% limits of agreement to be $\pm 9.3\%$. They concluded that ScvO₂ values are not interchangeable with SvO₂, but they reported that the trend of the two parameters

moved in the same direction. Reinhart et al.¹¹ also reported the limits of agreement between ScvO₂ and SvO₂ as 7.95% in critically ill patients. In our study, the 95% limits of agreement was 11.2% and was larger than the limits of agreement found in these previous studies. This finding suggests that the estimated SvO₂ values are not interchangeable with measured SvO₂. However, our results indicate that estimated SvO₂ demonstrates large changes when actual SvO₂ significantly changed. Rivers emphasized the importance of demonstrating trend of oxygen supply-demand relationship¹⁹ and we believe that our methods also enable physicians to detect deteriorated oxygen supply-demand balance without a central venous catheter. Although this technique can only be applied to tracheally intubated and mechanically ventilated patients, we believe this possibility is especially useful for the anesthetic management of patients with limited cardiac reserve or significant intraoperative blood loss when central venous catheterization is not indicated.

In conclusion, we demonstrated that SvO₂ can be estimated from the data obtained by the NICO monitor, Hb concentration, and assumption of VCO₂/VO₂ ratio in mechanically ventilated patients. The data suggest that this estimation is not interchangeable with the SvO₂ value obtained from a PAC, but it can detect large changes of SvO₂. This method may provide an estimate of balance of oxygen supply and demand without inserting a central venous catheter.

APPENDIX: THE FORMULA TO ESTIMATE SVO₂ BY CO, VCO₂, AND HEMOGLOBIN CONCENTRATION

$$\text{VO}_2 (\text{mL}/\text{min}) = \text{DO}_2 (\text{mL}/\text{min}) - 1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times \text{SvO}_2 (\%) \times 0.1$$

$$\text{VO}_2 (\text{mL}/\text{min}) = 1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times \text{SaO}_2 (\%) \times 0.1 - 1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times \text{SvO}_2 (\%) \times 0.1$$

$$\text{If } \text{SaO}_2 = \text{SpO}_2 \text{ and } \text{VO}_2 (\text{mL}/\text{min}) = \text{VCO}_2 (\text{mL}/\text{min})/R$$

R: respiratory quotient

$$\text{VCO}_2 (\text{mL}/\text{min})/R = 1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times \text{SpO}_2 (\%) \times 0.1 - 1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times \text{SvO}_2 (\%) \times 0.1$$

$$\text{SvO}_2 = \text{SpO}_2 - \frac{\text{VCO}_2 (\text{mL}/\text{min})/R}{1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times 0.1}$$

If R can be estimated as 0.85,

$$\text{SvO}_2 = \text{SpO}_2 - \frac{\text{VCO}_2 (\text{mL}/\text{min})/0.85}{1.36 \times \text{Hb} (\text{g}/\text{dL}) \times \text{CO} (\text{L}/\text{min}) \times 0.1}$$

Adapted from Mark and Slaughter.⁴

REFERENCES

1. Vedrinne C, Bastien O, De Varax R, Blanc P, Durand PG, Du Gres B, Bouvier H, Saroul C, Lehot JJ. Predictive factors for usefulness of fiberoptic pulmonary artery catheter for continuous oxygen saturation in mixed venous blood monitoring in cardiac surgery. *Anesth Analg* 1997;85:2-10
2. Marx G, Reinhart K. Venous oximetry. *Curr Opin Crit Care* 2006;12:263-8
3. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368-77
4. Mark JB, Slaughter TF. Cardiovascular monitoring. In: Miller RD, ed. *Miller's anesthesia*. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:1265-362
5. Levy RJ, Chiavacci RM, Nicolson SC, Rome JJ, Lin RJ, Helfaer MA, Nadkarni VM. An evaluation of a noninvasive cardiac output measurement using partial carbon dioxide rebreathing in children. *Anesth Analg* 2004;99:1642-7
6. Suzuki M, Koda S, Nakamura Y, Kawamura N, Shimada Y. The relationship between cardiac output measured by the thermodilution method and that measured by the carbon dioxide rebreathing technique during laparoscopic surgery. *Anesth Analg* 2005;100:1381-3
7. Bland JM, Altman DG. Measuring agreement in method comparison studies. *Stat Methods Med Res* 1999;8:135-60
8. Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. *J Biopharm Stat* 2007;17:571-82
9. Dueck MH, Klimek M, Appenrodt S, Weigand C, Boerner U. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. *Anesthesiology* 2005;103:249-57
10. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Changes in central venous saturation after major surgery, and association with outcome. *Crit Care* 2005;9:R694-R699
11. Reinhart K, Kuhn HJ, Hartog C, Bredle DL. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. *Intensive Care Med* 2004;30:1572-8
12. Varpula M, Karlsson S, Ruokonen E, Pettila V. Mixed venous oxygen saturation cannot be estimated by central venous oxygen saturation in septic shock. *Intensive Care Med* 2006;32:1336-43
13. Sander M, Spies CD, Foer A, Weymann L, Braun J, Volk T, Grubitzsch H, von Heymann C. Agreement of central venous saturation and mixed venous saturation in cardiac surgery patients. *Intensive Care Med* 2007;33:1719-25
14. Levy RJ, Stern WB, Minger KI, Montenegro LM, Ravishankar C, Rome JJ, Nicolson SC, Jobs DR. Evaluation of tissue saturation as a noninvasive measure of mixed venous saturation in children. *Pediatr Crit Care Med* 2005;6:671-5
15. Wei W, Zhu Z, Liu L, Zuo Y, Gong M, Xue F, Liu J. A pilot study of continuous transtracheal mixed venous oxygen saturation monitoring. *Anesth Analg* 2005;101:440-3
16. Jones AE, Kuehne K, Steuerwald M, Kline JA. End expiratory oxygen concentrations to predict central venous oxygen saturation: an observational pilot study. *BMC Emerg Med* 2006;6:9
17. Tachibana K, Imanaka H, Miyano H, Takeuchi M, Kumon K, Nishimura M. Effect of ventilatory settings on accuracy of cardiac output measurement using partial CO₂ rebreathing. *Anesthesiology* 2002;96:96-102
18. Kotake Y, Moriyama K, Innami Y, Shimizu H, Ueda T, Morisaki H, Takeda J. Performance of noninvasive partial CO₂ rebreathing cardiac output and continuous thermodilution cardiac output in patients undergoing aortic reconstruction surgery. *Anesthesiology* 2003;99:283-8
19. Rivers E. Mixed vs central venous oxygen saturation may be not numerically equal, but both are still clinically useful. *Chest* 2006;129:507-8

Epidural Cooling Minimizes Spinal Cord Injury after Aortic Cross-clamping through Induction of Nitric Oxide Synthase

Akiko Ishikawa, M.D.,* Atsuo Mori, M.D.,† Nobuyuki Kabei, Ph.D.,‡ Akihiro Yoshitake, M.D.,§ Takeshi Suzuki, M.D.,* Nobuyuki Katori, M.D.,* Hiroshi Morisaki, M.D.,|| Ryohei Yozu, M.D.,# Junzo Takeda, M.D.**

Background: By using a U-shaped lumen catheter, the authors examined the effects of epidural cooling on spinal cord injury after aortic cross-clamping (ACC), with a focus on changes of spinal cord blood flow and expression of inducible nitric oxide synthase.

Methods: Sixteen pigs were randomized into two groups: Control group (n = 8) or Cooling group (n = 8). In the latter, epidural cooling started at 30 min (baseline) before 45 min of ACC and persisted for the next 30 min of reperfusion period. Spinal cord blood flow and somatosensory-evoked potentials were assessed during peri-ACC period. At 48 h, we evaluated hind limb function by using Tarlov score and expression of inducible nitric oxide synthase on spinal cord using immunohistochemistry.

Results: After ACC, spinal cord blood flow dropped to a similar extent in both groups. During the reperfusion period, spinal cord blood flow increased up to 113% (103–124%), median (interquartile range), level transiently and decreased to 32% (22–47%) level *versus* baseline in the Control group, whereas it increased and remained at 92% (86–97%) level in the Cooling group. Simultaneously, somatosensory-evoked potentials showed that onset of loss time was delayed and recovery time was shortened in the Cooling group. Tarlov scores in the Cooling group were significantly higher and accompanied by normal-appearing motor neurons and significantly greater expression of inducible nitric oxide synthase on spinal cord *versus* the Control group.

Conclusions: This study shows that epidural cooling during ACC minimized the risk of spinal cord injury, possibly by preventing delayed hypoperfusion and upregulating inducible nitric oxide synthase expression.

ALTHOUGH the outcome of surgical repair for thoracoabdominal aortic aneurysm has been improved as a result of a marked advance of perioperative care and surgical techniques, paraplegia, occurring with high incidence between 6 and 16%, is not yet resolved as the most severe complication.^{1,2} Although the underlying mechanisms remain to be fully determined, several factors, such as interruption of blood flow and/or increased

cerebrospinal fluid pressure, have been proposed.³ Clinically available protection of spinal cord consists of two approaches, *i.e.*, preservation of regional blood supply and reduction of oxygen demand during aortic cross-clamping (ACC). The former can be achieved with intercostal implantation, left heart bypass grafting, or cerebrospinal fluid drainage, whereas the latter with various pharmacologic agents and hypothermia.³⁻⁵ Hypothermia is one of the most promising ways; however, given at systemic level detrimental complications such as coagulation abnormality, cardiac arrhythmia and pulmonary dysfunction could be unmasked.^{6,7}

Cambria *et al.* demonstrated that regional hypothermia of spinal cord by infusion of iced saline into epidural space reduced spinal cord injury without systemic complications.⁸ However, another concern has been raised to question whether this approach increases cerebrospinal fluid pressure associated with further deterioration of spinal cord perfusion. We, therefore, developed a newly designed epidural cooling catheter with closed perfusion circuit and demonstrated protective effects against spinal cord injury without elevating cerebrospinal fluid pressure.⁹ Other investigators also described as a preliminary report that regional cooling with a closed perfusion system could be a good approach to prevent spinal cord injury during aortic surgery.¹⁰ We, therefore, designed the current study to examine the effects of epidural cooling with focus on the changes of blood flow and somatosensory-evoked potentials (SEP) of spinal cord during peri-ACC periods, accompanied by evaluation of neurologic outcomes in a porcine model. In spinal cord injury induced by ischemia, activation of inducible nitric oxide synthase (iNOS) and subsequent nitric oxide production has been appreciated as a marker and therapeutic target.^{11,12} Whereas two time periods of moderate to excessive nitric oxide discharge after spinal cord ischemia have been defined, *i.e.*, immediately after injury and several hours to days later, previous studies indicated that iNOS expression was mainly responsible for the latter.¹³⁻¹⁵ In the current study, we therefore assessed histologic alterations concurrent with iNOS expression on spinal cord at 48 h after ischemic insults.

Materials and Methods

This experimental protocol was approved by the Animal Care Committee of Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama, Japan.

* Instructor, || Associate Professor, ** Professor, Department of Anesthesiology, § Instructor, # Professor, Department of Cardiovascular Surgery, Keio University School of Medicine; † Chief, Department of Cardiovascular Surgery, Kawasaki Municipal Hospital, Kanagawa; ‡ Chief Researcher, Saitama Cardiovascular and Respiratory Center, Saitama.

Received from Departments of Anesthesiology and Cardiovascular Surgery, Keio University School of Medicine, and Department of Cardiovascular Surgery, Kawasaki Municipal Hospital, and Saitama Cardiovascular and Respiratory Center, Japan. Submitted for publication March 9, 2009. Accepted for publication June 26, 2009. Support was provided solely from institutional and/or departmental sources. Presented in part at the Annual Meeting of American Society of Anesthesiologists, Orlando, Florida, October 21, 2008.

Address correspondence to Dr. Morisaki: Department of Anesthesiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. morisaki@z8.keio.jp. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY's articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

Animal Model and Preparatory Surgery

Male domestic pigs (40–50 kg) were studied after a 3- to 7-day period of acclimatization in our laboratory. The animals were initially anesthetized with intramuscular ketamine (10 mg/kg), and the trachea was intubated. With isoflurane anesthesia in oxygen, respiratory rate and tidal volume were adjusted to maintain normocapnia. Under the right lateral decubitus position, a cooling-warming blanket was applied to maintain rectal temperature at approximately 36°C throughout the study periods. An epidural cooling catheter (Unitika, Tokyo, Japan), which was developed by our group,⁹ was inserted at L2 level *via* laminectomy and removal of ligamentum flavum. The catheter has 16-gauge outer diameter and 35-cm length and a closed countercurrent lumen, allowing fluid to circulate the inside. The tip of catheter directed into cephalad of epidural space was placed at Th6 level, which was confirmed for each animal by using an x-ray examination. The other side of this catheter was connected to an external roller pump and heat exchanger (MERA modular type and CP-4; Senko Medical Instrument, Tokyo, Japan), which enabled cooled-saline to circulate inside the catheter (fig. 1). Epidural cooling catheter, cooling unit, and circulating pump made up the circuit. Distilled water was not infused into epidural space directly but was circulated as a coolant within the U-shaped lumen of epidural catheter and extracorporeal circuit. This system and an epidural catheter with closed countercurrent lumen could provide regional cord cooling without increasing intrathecal pressure as described previously.⁹ Bipolar electrodes for monitoring of SEP were placed in epidural space at L4/5 level for stimulation and at Th5/6 level for record. To continuously monitor epidural and subarachnoid temperatures, thermistor probes were placed on dorsal dura and in subarachnoid space at L3 level. Arterial catheters were inserted in right axillary artery (proximal to clamp site) and right femoral artery to measure arterial blood pressure (distal to clamp site), respectively. Heart rate




Fig. 1. Schematic drawing of continuous cord cooling system and epidural cooling catheter with a closed countercurrent lumen.




Fig. 2. Study protocol.

and rectal temperature were continuously monitored throughout the study periods.

Study Protocol

After the placement of epidural cooling and monitoring catheters, 16 domestic pigs were randomly allocated into two groups by using a computer-generated random number. Control group (n = 8) received placement of an epidural catheter alone, Cooling group (n = 8) received regional cooling by continuous cord cooling system with an epidural cooling catheter (fig. 2). The animals then underwent thoracotomy at the fourth and seventh intercostals under sterile conditions. After surgical preparation for ACC, heparin sulfate (60 U/kg) was injected to provide systemic anticoagulation. In Cooling group, epidural cooling by circulating cooled saline (4°C) at a rate of 75–90 ml/min was started 30 min before ACC and continued until 30 min after ACC (105 min for total epidural cooling time). All animals underwent segmental ACC for 45 min between the distal site to left subclavian artery and the proximal site to the diaphragm. Complete ACC was confirmed by the loss of femoral artery pressure (distal blood pressure) during ACC. Transient hypertension detected at the right axillary artery after ACC was regulated with intermittent injection of intravenous nicardipine hydrochloride. Blood pressure after declamping was maintained with fluid resuscitation and intravenous injection of phenylephrine hydrochloride. After a 3-h examination period, all catheters and monitors were removed and wounds were closed. When emergence from anesthesia was achieved, the trachea was extubated, and the animal was returned to the cage for subsequent examination of neurologic outcome in hind limb for 48 h.

Measurements of Blood Flow and SEP of Spinal Cord

Blood flow to spinal cord (SCBF) was continuously measured by using laser-Doppler flowmetry (Model LBF-III; Biomedical Science, Tokyo, Japan) adjusted for high-flow measurement (12 kHz, gain 1 or 3) and a time constant of 3.0 s. The signal was continuously recorded on a 2-channel strip-card recorder and referred to as SCBF. The tip of laser-Doppler probe was implanted on the epidural surface at L2 level, because porcine spinal